Targeting two parts of the signaling pathway simultaneously may increase treatment efficacy or delay the development of tumor resistance, as observed clinically in melanomas harboring RAF mutations managed with treatments targeting RAF and MEK (Flaherty et al, 2012). Here, MAP2K7 is linked to melanoma.